share_log

Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma

Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma

Soligenix開始爲皮膚T細胞淋巴瘤藥物候選者的第三階段研究招募患者。
MT Newswires ·  12/16 21:05

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論